Considering ongoing evidence regarding the high number of survivors showing lung fibrosis persisting for months after discharge, it would be of great interest to evaluate the Gas6/TAM involvement in such progressive and irreversible disease sequelae, to promptly establish the appropriate pharmacological therapy, thus increasing survivors’ quality of life. The gene discussed is GAS6; the disease is pulmonary fibrosis.